Aligos Discontinues Development of its Antisense Oligonucleotide Drug Candidate ALG-020572 in Subjects with Chronic Hepatitis B and Pivots Internal Strategic Emphasis to its Small Molecule Portfolio
Dosing in the first cohort discontinued after multiple reports of ALT flares suggestive of drug-induced…
Ascend Education Guides Over 500 Hong Kong Migrant Families in Navigating the UK Education System